Hemophilia A Clinical Trials

Find Hemophilia A Clinical Trials Near You

A Multi-institution Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa. Participants will undergo assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period. The study aims to evaluate whether differences in prophylactic therapy are associated with differences in bone health outcomes.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 30
Maximum Age: 50
Healthy Volunteers: f
View:

• The participant or legally authorized representative is willing and able to provide written informed consent.

• Diagnosis of severe hemophilia A (factor VIII activity \< 1%).

• Male sex.

• Age between 30 and 50 years (inclusive).

• BMI between 18.5 and 40 kg/m2

• The participant must have been on prophylaxis with Efanesoctocog alfa or Emicizumab for at least 3 months prior to enrollment and intend to remain on the current regimen for the next 5 years.

• Willingness to undergo all research procedures, including DEXA scans and the collection of blood samples.

• Willingness to complete all standard-of-care bleeding and treatment logs.

Locations
United States
Arkansas
Arkansas Children's
RECRUITING
Little Rock
Contact Information
Primary
Carol D Pierce, RN
piercecarold@uams.edu
501-364-4440
Time Frame
Start Date: 2026-09-21
Estimated Completion Date: 2032-09
Participants
Target number of participants: 50
Treatments
Patients with Severe Hemophilia A on Efanesoctocog alfa prophylaxis
Participants with severe hemophilia A receiving prophylaxis with efanesoctocog alfa as part of routine clinical care. Participants will undergo longitudinal assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period.
Patients with Severe Hemophilia A on Emicizumab prophylaxis
Participants with severe hemophilia A receiving prophylaxis with emicizumab as part of routine clinical care. Participants will undergo longitudinal assessments of bone mineral density, bone remodeling biomarkers, thrombin generation, plasmin generation, and joint health over a five-year period.
Related Therapeutic Areas
Sponsors
Collaborators: Genzyme, a Sanofi Company
Leads: Arkansas Children's Hospital Research Institute

This content was sourced from clinicaltrials.gov